Compounds for use in inducing myocardial perfusion recovery
AssigneeEpoqe Pharma ApS
InventorsAnette SAMS NIELSEN, Lars Ingvar Herbert Edvinsson
Life of this patent
Estimating the term…
Abstract
A calcitonin gene-related peptide (CGRP) compound selected from N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy }ethoxy)acetyl][Ser1]alpha-human CGRP peptide (α-CGRP-analogue), or derivatives thereof; or N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyryl-amino]-ethoxy }ethoxy)acetyl][Ser1]beta-human CGRP peptide (β-CGRP-analogue), or derivatives thereof, is produced for use in inducing myocardial perfusion recovery, in connection with acute myocardial infarction (AMI), by activating any CGRP family of receptors with a larger CGRP compound:CGRP potency ratio in coronary artery than in mesenteric artery.
Claims19
1-29. (canceled)
A method for the treatment of acute myocardial infarction (AMI), the method comprising:
- administering a calcitonin gene-related peptide (CGRP) compound in a subject in need thereof,
- wherein the CGRP compound is N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyrylamino]ethoxy } ethoxy)acetyl][Ser1 ]alpha-human CGRP peptide (α-CGRP-analogue), and pharmaceutically acceptable salts and solvates thereof.
Dependencies are inferred from the claim text.